78 related articles for article (PubMed ID: 18800614)
41. Expanding dasatinib beyond KIT in acute myeloid leukemia.
Welch JS
Haematologica; 2020 Dec; 105(12):2708-2710. PubMed ID: 33256372
[No Abstract] [Full Text] [Related]
42. Medicinal Chemistry--Second Joint French/Swiss Meeting. 1-4 July 2003, Beaune, France.
Kurz G
IDrugs; 2003 Aug; 6(8):755-7. PubMed ID: 12971394
[No Abstract] [Full Text] [Related]
43. IPK'2001. Abstracts of the 2nd International Conference on Inhibitors of Protein Kinases and the Workshop on Computer-Aided Drug Design. September 9-15, 2001. Warsaw, Poland.
Cell Mol Biol Lett; 2001; 6(2B):447-565. PubMed ID: 11787496
[No Abstract] [Full Text] [Related]
44. Olutasidenib (Rezlidhia) for acute myeloid leukemia.
Med Lett Drugs Ther; 2023 Apr; 65(1673):e58-e59. PubMed ID: 37020343
[No Abstract] [Full Text] [Related]
45. [Molecular pathogenesis and treatment of leukemia].
Kurokawa M
Nihon Naika Gakkai Zasshi; 2011 Mar; 100(3):796-800. PubMed ID: 21618815
[No Abstract] [Full Text] [Related]
46. AEE788 is a vascular endothelial growth factor receptor tyrosine kinase inhibitor with antiproliferative and proapoptotic effects in acute myeloid leukemia.
Barbarroja N; Torres LA; Rodriguez-Ariza A; Valverde-Estepa A; Lopez-Sanchez LM; Ruiz-Limon P; Perez-Sanchez C; Carretero RM; Velasco F; López-Pedrera C
Exp Hematol; 2010 Aug; 38(8):641-52. PubMed ID: 20380868
[TBL] [Abstract][Full Text] [Related]
47. FLT3/ ITD regulates leukaemia cell adhesion through α4β1 integrin and Pyk2 signalling.
Katsumi A; Kiyoi H; Abe A; Tanizaki R; Iwasaki T; Kobayashi M; Matsushita T; Kaibuchi K; Senga T; Kojima T; Kohno T; Hamaguchi M; Naoe T
Eur J Haematol; 2011 Mar; 86(3):191-8. PubMed ID: 21114537
[TBL] [Abstract][Full Text] [Related]
48. [Possibility of targeting FLT3 kinase for the treatment of leukemia].
Kiyoi H
Rinsho Ketsueki; 2005 Mar; 46(3):187-97. PubMed ID: 16447713
[No Abstract] [Full Text] [Related]
49. [New therapeutic option for leukemia patients, with FLT3/Aurora kinase inhibitor, KW-2449: strategy and comparison with other kinase inhibitors].
Shiotsu Y
Rinsho Ketsueki; 2008 Aug; 49(8):641-9. PubMed ID: 18800614
[No Abstract] [Full Text] [Related]
50. FLT3 inhibitors for the treatment of acute myeloid leukemia.
Wiernik PH
Clin Adv Hematol Oncol; 2010 Jun; 8(6):429-36, 444. PubMed ID: 20733555
[TBL] [Abstract][Full Text] [Related]
51. [FLT3 kinase inhibitors for the treatment of acute leukemia].
Kiyoi H
Rinsho Ketsueki; 2010 Jun; 51(6):384-9. PubMed ID: 20622483
[No Abstract] [Full Text] [Related]
52.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
53.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
54.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
55.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
56.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
57.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
58.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
